2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Chronic kidney disease (CKD) is defined by a low glomerular filtration rate or high
albuminuria, and affects 15–20% of adults globally. CKD increases the risk of various …
albuminuria, and affects 15–20% of adults globally. CKD increases the risk of various …
Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy …
M Packer - Circulation, 2022 - Am Heart Assoc
SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …
on the evolution and progression of cardiomyopathy and nephropathy, which is …
Japanese clinical practice guideline for diabetes 2019
E Araki, A Goto, T Kondo, M Noda, H Noto… - Diabetology …, 2020 - Springer
The current guideline represents the 6th edition of the “Japanese Clinical Practice Guideline
for Diabetes” which has been revised every three years since its first appearance in 2004 to …
for Diabetes” which has been revised every three years since its first appearance in 2004 to …
[HTML][HTML] Daprodustat for the treatment of anemia in patients undergoing dialysis
AK Singh, K Carroll, V Perkovic… - … England Journal of …, 2021 - Mass Medical Soc
Background Among patients with chronic kidney disease (CKD), the use of recombinant
human erythropoietin and its derivatives for the treatment of anemia has been linked to a …
human erythropoietin and its derivatives for the treatment of anemia has been linked to a …
Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents
J Portolés, L Martín, JJ Broseta, A Cases - Frontiers in Medicine, 2021 - frontiersin.org
Anemia is a common complication in chronic kidney disease (CKD), and is associated with a
reduced quality of life, and an increased morbidity and mortality. The mechanisms involved …
reduced quality of life, and an increased morbidity and mortality. The mechanisms involved …
Iron deficiency anaemia revisited
MD Cappellini, KM Musallam… - Journal of internal …, 2020 - Wiley Online Library
Iron deficiency anaemia is a global health concern affecting children, women and the
elderly, whilst also being a common comorbidity in multiple medical conditions. The …
elderly, whilst also being a common comorbidity in multiple medical conditions. The …
Anemia and iron deficiency in heart failure: current concepts and emerging therapies
IS Anand, P Gupta - Circulation, 2018 - Am Heart Assoc
Anemia and iron deficiency are important and common comorbidities that often coexist in
patients with heart failure. Both conditions, together or independently, are associated with …
patients with heart failure. Both conditions, together or independently, are associated with …
[HTML][HTML] Roxadustat for anemia in patients with kidney disease not receiving dialysis
N Chen, C Hao, X Peng, H Lin, A Yin… - … England Journal of …, 2019 - Mass Medical Soc
Abstract Background Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …
Vadadustat in patients with anemia and non–dialysis-dependent CKD
GM Chertow, PE Pergola, YMK Farag… - … England Journal of …, 2021 - Mass Medical Soc
Background Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor,
a class of drugs that stabilize HIF and stimulate erythropoietin and red-cell production …
a class of drugs that stabilize HIF and stimulate erythropoietin and red-cell production …